Hatch Waxman > Nova Content
Federal Circuit Summary
Before O’Malley, Reyna, and Hughes. Appeal from the District Court for the Northern District of California... Read More »
Federal Circuit Summary
Before Newman, Dyk, and Taranto. Appeal from the United States District Court for the District of Delaware.
Summary: ... Read More »
Federal Circuit Summary
Before Newman, Hughes, and Stoll. Appeal from the United States District Court for the District of Delaware
Summary: Objective indicia ... Read More »
On July 20, 2018, the Federal Circuit held that tribal sovereign immunity is not available as a defense in IPR.
Allergan Pharmaceuticals owned patents that it had ... Read More »
Federal Circuit Summary
Before Dyk, Moore, and Reyna. Appeal from the Patent Trial and Appeal Board.
Summary: Tribal sovereign immunity does not shield... Read More »
Federal Circuit Summary
Before Moore, Linn, and Chen. Appeal from the United States District Court for the District of Delaware.
Summary: A prior art... Read More »
Federal Circuit Summary
Before Newman, Lourie, and Reyna. Appeal from the Patent Trial and Appeal Board.
Summary: References were sufficiently... Read More »
On June 25th, 2018, the U.S. Food and Drug Administration (FDA) approved the drug, Epidiolex, for the treatment of seizures associated with two rare forms of... Read More »
I have posted twice recently on the Fed. Cir.’s opinion in Vanda Pharms., Inc. v. West-Ward Pharm. Int’l, Ltd., Appeal no. 2016-2107 (Fed. Cir., April 18, ... Read More »
Federal Circuit Summaries
Before Reyna, Bryson, and Stoll. Appeal from the Patent Trial and Appeal Board.
Summary: A petitioner in an Inter Partes Review may... Read More »
Federal Circuit Summary
Before Wallach, O’Malley, and Schall. Appeal from the Patent Trial and Appeal Board.
Summary: PGR petitioner has standing... Read More »
Federal Circuit Summary
Before Moore, Mayer, and Stoll. Appeal from the United States District Court for the District of New Jersey.
Summary: Plain... Read More »
Federal Circuit Summary
Before Prost, Lourie and Hughes. Appeal from the United States District Court for the District of Delaware.
Summary: When... Read More »
Lundbeck Pharmaceutical Company, headquartered in Denmark, recently announced the acquisition of Prexton Therapeutics B.V. for $1.1 billion (U.S.)(1). Lundbeck... Read More »
Xeris Pharmaceuticals, Inc. (“Xeris”) recently announced successful completion of both adult and pediatric clinical studies for its glucagon rescue pen... Read More »
The PTAB dismissed the Saint Regis Mohawk Tribe’s attempt to avoid IPR of patents covering Restasis®, which Allergan transferred to the Tribe in a highly... Read More »
As an introduction to this topic, please reread my post of July 5, 2017 about The Cleveland Clinic v. True Health Diagnostics, subtitled “Time to Redefine... Read More »
Federal Circuit Summary
In Medicines Co. v. Hospira, Inc., 2014-1469; 2014-1504 (Dyk, Wallach, Hughes), the Federal Circuit affirmed the district court’s... Read More »
Federal Circuit Summary
Before Taranto, Clevenger, and Stoll. Appeal from the United States District Court for the District of Delaware.
Summary: Proceeding... Read More »
Written by Daniel A. Kamkar and Michael L. Fuller
On October 9, 2017, California Governor Jerry Brown signed the new drug price transparency bill SB 17.[1] ... Read More »